Brief: Dermapharm Q1 Adjusted EBITDA EUR 87.4 Million
May 13 (Reuters) - Dermapharm Q1 revenue EUR 305.8 million. Q1 EBITDA margin 29.8% Q1 adjusted EBITDA margin 28.6% Q1 EBITDA EUR 91.2 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit